News | September 09, 2025
Ichnos Glenmark Innovation receives upfront payment of $700 million from AbbVie
The payment is in accordance with the agreed contractual terms
The payment is in accordance with the agreed contractual terms
Biocytogen will provide proprietary, fully human antibodies derived from its RenMice platform for evaluation in Merck’s antibody-conjugated LNP services
Agreement further expands Aptar Pharma’s leading position in nasal delivery solutions and addresses significant unmet needs of delivering drugs locally over extended periods
Under the terms of this agreement, Synthon will be responsible for obtaining final regulatory approval for its Ozanimod Capsules product
Now integrates with Abbott’s instinct sensor and approved for type 2 diabetes
Replicate will receive research funding and could potentially receive up to approximately US$550 million
Accro will retain global rights to develop, manufacture, and commercialize AC-201 (excluding Chinese Mainland, Hong Kong SAR, and Macau SAR)
The suite represents a multi-million-dollar investment in equipment upgrades and enhancements to improve the site's capabilities
Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the collaboration upon option exercise
Under an exclusive distribution agreement, Sartorius Stedim Biotech will offer Nanotein’s lead products globally
Subscribe To Our Newsletter & Stay Updated
